Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment

J Rheumatol. 1994 Oct;21(10):1860-4.

Abstract

Objective: To determine the levels of serum soluble intercellular adhesion molecule 1 (sICAM-1) in patients with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) prior and during steroid therapy.

Methods: Sixteen patients with PMR and/or GCA had complete clinical and laboratory investigations at diagnosis before treatment and 9 patients were followed during 6 months of steroid therapy. Serum sICAM-1 levels were measured by ELISA:

Results: Serum ICAM-1 levels were higher in the patient group compared to a control population. No significant correlation was found between serum sICAM-1 levels and other indices of disease activity. After steroid administration, a dramatic fall in serum sICAM-1 levels was observed at the end of the first week and persisted until the end of the study period, paralleling clinical and laboratory disease remission.

Conclusion: Serum sICAM-1 levels paralleled disease activity in PMR and/or GCA. Steroid treatment induced a rapid normalization of the serum sICAM-1 levels.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dexamethasone / therapeutic use*
  • Enzyme-Linked Immunosorbent Assay
  • Giant Cell Arteritis / blood
  • Giant Cell Arteritis / drug therapy
  • Humans
  • Hydrocortisone / therapeutic use*
  • Intercellular Adhesion Molecule-1 / blood*
  • Polymyalgia Rheumatica / blood*
  • Polymyalgia Rheumatica / drug therapy*
  • Prospective Studies

Substances

  • Intercellular Adhesion Molecule-1
  • Dexamethasone
  • Hydrocortisone